贝伐珠单抗联合放化疗对宫颈癌疗效的Meta分析  

A Meta-Analysis of the Efficacy of Bevacizumab in Combination With Chemoradiotherapy in Cervical Cancer

作　　者：毛先华[1] 曾彩虹 孙移娇 王志文[1] 任森 霍伦 MAO Xianhua;ZENG Caihong;SUN Yijiao;WANG Zhiwen;REN Sen;HUO Lun(Key Laboratory of Chronic Noncommunicable Diseases,Yueyang Vocational Technical College,Yueyang Hunan 414006,China;Department of Gynecology,Yueyang Hospital Affiliated to Hunan Normal University/Yueyang People′s Hospital,Yueyang Hunan 414000,China;Clinical College,Changsha Health Vocational College,Changsha Hunan 410100,China)

机构地区：[1]岳阳职业技术学院慢性病重点实验室,湖南岳阳414006 [2]湖南师范大学附属岳阳医院/岳阳市人民医院妇科,湖南岳阳414000 [3]长沙卫生职业学院临床学院,湖南长沙410100

出　　处：《中国卫生标准管理》2024年第11期104-109,共6页China Health Standard Management

基　　金：2021年湖南省职业院校教育教学改革研究项目(ZJBZ2021140)。

摘　　要：目的评价贝伐珠单抗联合放化疗治疗宫颈癌的疗效及治疗过程中的安全性。方法对中文数据库维普及英文数据库PubMed等中关于贝伐珠单抗联合放化疗治疗宫颈癌的研究进行检索,收集2010—2023年相关的随机对照试验。采用Review Manager 4.2软件分析患者的完全缓解、部分缓解、疾病稳定及不良反应的发生率,绘制漏斗图评价发表偏倚情况。结果纳入符合本研究的文献9篇,共654例患者(试验组327例,对照组327例)。贝伐珠单抗联合放化疗可提高宫颈癌患者完全缓解、部分缓解和疾病稳定的发生率,不良反应的发生率与单纯放化疗相比,差异无统计学意义(P>0.05)。漏斗图显示纳入的研究尚不认为存在发表偏倚。结论贝伐珠单抗联合放化疗治疗宫颈癌的疗效优于单纯放化疗,与单纯放化疗不良反应的发生率相近。Objective To evaluate the efficacy and safety of bevacizumab combined with chemoradiotherapy in the treatment of cervical cancer.Methods The studies on the treatment of cervical cancer in the Chinese database PubMed et al.were searched,and the randomized controlled trials from 2010 to 2023 were collected.Review Manager 4.2 was used to analyze the incidence of complete response,partial response,stable disease,and adverse reactions in patients.Funnels were plotted to assess publication bias.Results Nine articles in the literature with a total of 654 patients(327 in the experimental group and 327 in the control group)were included.Bevacizumab combined with chemoradiotherapy increased the incidence of complete remission,partial remission,and disease stabilization in patients with cervical cancer,and there was no difference in the incidence of adverse reactions compared with chemoradiotherapy alone(P>0.05).Funnel plots show that the included studies were not considered to be at publication bias.Conclusion The efficacy of bevacizumab combined with chemoradiotherapy in the treatment of cervical cancer was better than that of chemoradiotherapy alone,and the incidence of adverse reactions was similar to that of chemoradiotherapy alone.

关 键 词：宫颈癌 贝伐珠单抗 同步放化疗 随机对照资料 META分析 疗效 

分 类 号：R737[医药卫生—肿瘤]